Blog
RSS FeedPosted by Michael Wonder on 25 Aug 2025
Recommendations made the PBAC – July 2025
22 August 2025 - The recommendations from the July 2025 PBAC meeting are now available. ...
Posted by Michael Wonder on 25 Aug 2025
Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer
23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...
Posted by Michael Wonder on 25 Aug 2025
Injectable form of Ocrevus for relapsing remitting multiple sclerosis recommended for PBS listing
22 August 2025 - This new form of ocrelizumab is given as an injection under the skin (subcutaneously), takes a much ...
Posted by Michael Wonder on 24 Aug 2025
New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year
23 August 2025 - New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k/year. ...
Posted by Michael Wonder on 22 Aug 2025
Health Canada grants marketing authorisation for an additional indication of Bayer's Nubeqa (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer
21 August 2025 - Bayer is pleased to announce that Health Canada has granted marketing authorisation for its oral androgen receptor ...
Posted by Michael Wonder on 21 Aug 2025
Dawnzera (donidalorsen) approved in the US as first and only RNA targeted prophylactic treatment for hereditary angioedema
21 August 2025 - Offers longest dosing option for hereditary angioedema, with dosing every 4 or 8 weeks. ...
Posted by Michael Wonder on 20 Aug 2025
First of its kind Ozempic listing for kidney disease
19 August 2025 - Regulators have approved Ozempic’s use for kidney disease treatment, opening the door to new combination therapies. ...
Posted by Michael Wonder on 20 Aug 2025
Madrigal receives European Commission approval for Rezdiffra (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis
19 August 2025 - Conditional marketing authorisation is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra ...
Posted by Michael Wonder on 20 Aug 2025
Health Canada approves dual immunotherapy Opdivo plus Yervoy for colorectal and liver cancers
19 August 2025 - Bristol Myers Squibb Canada today announced that Health Canada has approved Opdivo (nivolumab) in combination with ...
Posted by Michael Wonder on 20 Aug 2025
Health Canada approves Ozempic to reduce the risk of sustained eGFR decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
19 August 2025 - Novo Nordisk announced today that Ozempic (semaglutide injection) is now approved as the first and only ...
Posted by Michael Wonder on 20 Aug 2025
PTC Therapeutics receives complete response letter for vatiquinone NDA
19 August 2025 - PTC Therapeutics announced today that the US FDA has issued a complete response letter related to ...
Posted by Michael Wonder on 19 Aug 2025
Pfizer Canada and BioNTech receive Health Canada approval of LP.8.1 variant adapted COVID-19 vaccine
18 August 2025 - LP.8.1 variant adapted COVID-19 vaccine Cominaty is now authorised in Canada for individuals 6 months of age ...
Posted by Michael Wonder on 19 Aug 2025
Iovance’s Amtagvi (lifileucel) receives Health Canada approval for advanced melanoma
18 August 2025 - Iovance Biotherapeutics today announced Health Canada has issued a Notice of Compliance with Conditions for Amtagvi ...
Posted by Michael Wonder on 19 Aug 2025
Valneva’s chikungunya vaccine Ixchiq now authorised in Canada for individuals aged 12 and plder
18 August 2025 - Valneva today announced that Health Canada has granted marketing authorisation for its single dose vaccine, Ixchiq, ...
Posted by Michael Wonder on 18 Aug 2025
European Commission grants approval of Ogsiveo
18 August 2025 - Merck KGaA announced today that the European Commission granted marketing authorisation for Ogisiveo (nirogacestat), an oral gamma ...